Posted inBiogen Inc Drugs (Pharmaceuticals) Food and Drug Administration Medicare Prices (Fares, Fees and Rates) Recalls and Bans of Products Regulation and Deregulation of Industry
Biogen Abandons Its Controversial Alzheimer’s Drug Aduhelm
The pharmaceutical company will give up its ownership rights to the drug and stop a clinical trial that had been aimed at confirming whether it works.